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Abstract. Background: Obesity is a major risk factor for cardiovascular disease, type 2 diabetes, 
high blood pressure, sleep apnea, psychological issues, some musculoskeletal conditions, and 
some cancers. The aim of the study to evaluate the correlation between BMI and risk factor of 
non-alcoholic fatty liver disease (NAFLD). Method: The research was conducted cross-
sectionally in NAFLD patients who were treated at RSUP H Adam Malik Medan and got 
approval from the Ethics Commission for Health Research. Sample research is NAFLD patients 
who are taken in consecutive sampling that meets the criteria of inclusion and exclusion.  Body 
mass index (BMI) is obtained by dividing a person's weight in kilograms by their height in square 
meters, define obesity (OB) if BMI  >  25,  overweight  (OW) BMI  23-24.9, and normoweight 
(NW) BMI 18.5-22.9. Diagnose NAFLD by performing ultrasound examination, resistin and 
adiponectin examination with ELISA (Sandwich Immunoassay), liver function according to 
IFCC (International Federation of Clinical Chemistry), and albumin checked by BCG method. 
Result: There were 67 patients (NM=32, OW=15, OB=20) NAFLD with an average age of 42.1± 
11.9 years,  Comparison of NAFLD risk factors in normoweight, overweight, and obesity, 
showing very significant results (all p<0.001). There is a very significant correlation between 
BMI and all NAFLD risk factors (all p<0.001). Conclusion: There are very significant correlates 
between BMI and all inflammatory factors of NAFLD. 
Keyword: BMI, NAFLD risk factors 
Abstrak. Latar Belakang : Obesitas adalah faktor risiko utama untuk penyakit kardiovaskular, 
Diabetes tipe 2, tekanan darah tinggi, apnoea waktu tidur, masalah psikologis, beberapa kondisi 
muskuloskeletal dan kanker. Tujuan penelitian untuk mengevaluasi korelasi antara BMI dan 
faktor risiko non-alcoholic fatty liver disease (NAFLD) Metode: Penelitian dilakukan secara 
cross sectional  pada pasien NAFLD yang dirawat di RSUP H Adam Malik Medan dan mendapat 
persetujuan dari Komisi Etik Penelitian Kesehatan. Sampel penelitian adalah pasien NAFLD 
yang diambil consecutive sampling  yang memenuhi kriteria inklusi dan ekslusi. Indeks massa 
tubuh (IMT) diperoleh dengan membagi berat badan dalam kilogram dengan tinggi badan 
mereka di meter persegi.  Definisikan obesitas (OB) jika IMT > 25, kelebihan berat badan (OW)  
IMT 23-24,9 dan normoweight  (NW)  IMT  18,5-22,9. Diagnosa NAFLD dengan melakukan 
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pemeriksaan USG, pemeriksaan resistin dan adiponektin dengan ELISA (Sandwich 
Immunuassay), fungsi hati menurut IFCC (International Federation of Clinical Chemistry), dan 
albumin diperiksa dengan metode BCG. Hasil: Terdapat 67 pasien (NM=32, OW=15, OB=20) 
NAFLD dengan usia rata-rata 42,1± 11,9 tahun,  Faktor risiko NAFLD pada normoweight, 
kelebihan berat badan dan obesitas, menunjukan hasil sangat signifikan (semua P<0.001). Ada 
korelasi yang sangat signifikan antara IMT dengan faktor semua risiko NAFLD (semua 
P<0.001). Kesimpulan:  Ada korelasi yang sangat signifikan antara IMT dengan semua faktor 
inflamasi  NAFLD. 
Kata Kunci: IMT,  faktor risiko NAFLD 
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1 Introduction 
Excessive calorie consumption relative to expenditure, intake of unhealthy diets, and lack of physical 
activity are globally. [1]  Fuelling an increase in the prevalence of poor metabolic health, even in 
individuals of normal weight. [2]  Consequently, this trend entails increased risk of various metabolic 
disorders, including non-alcoholic fatty liver disease (NAFLD), recently re-named metabolic 
associated fatty liver disease (MAFLD), which affects about a quarter of the global population. [3] 
Non-alcoholic fatty liver disease (NAFLD) represents a condition of excessive accumulation of fat in 
the liver of people consuming alcohol at amounts below risk levels. [4] The condition may be limited 
to excessive liver fat (NAFL) or progress to necroinflammation and fibrosis non-alcoholic 
steatohepatitis (NASH) to NASH-cirrhosis, [5] and eventually to hepatocellular carcinoma. [6] 
The prevalence of NAFLD in the general population is about 25%, peaking at more than 30% in the 
Middle East and South America and as low as 13% in Africa. [7] Although NAFLD is associated 
with metabolic syndrome and obesity rates, [8] a recent meta-analysis of 84 studies (more than 10 
million cases) concluded that 40.8% (95% confidence interval 36.6% to 45.1%) of patients with 
NAFLD were non-obese and 19.2% (15.9% to 23.0%) were definitely lean. [9] These rates were 
calculated with body mass index (BMI) a djusted for ethnicity that is less than 23 for normal weight 
and 23.0-27.5 for overweight in Asians. 
Increased levels of markers of inflammation such as high sensitivity C-Reactive Protein (hs-CRP), 
certain interleukins and Tumor Necrosis Factor Alpha (TNF-alpha) have been linked with metabolic 
disorders, cardiovascular diseases as well as an increased risk of mortality. Obesity also influences 
the development of these outcomes. Better understanding of the link between weight gain, obesity 
and the development of low-grade chronic inflammation could prove useful in addressing these major 
public health issues. 
The aim of the study was to analyse whether BMI correlate with parameter risk factors NAFLD. 
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2 Method  
The research was conducted cross sectionally in NAFLD patients who treated at RSUP H Adam 
Malik Medan and got approval from the Ethics Commission for Health Research. Sample research is 
NAFLD patients who are taken in consecutive sampling that meets the criteria of inclusion and 
exclusion.  Body mass index (BMI) is obtained by dividing a person's weight in kilograms by their 
height in square meters, define of  obesity (OB) if BMI  >  25,  overweight  (OW) BMI  23-24.9 and 
normoweight (NW) BMI 18.5-22.9. 
Diagnose NAFLD by performing ultrasound examination, resistin and adiponectin examination with 
ELISA (Sandwich Immunuassay), liver function according to IFCC (International Federation of 
Clinical Chemistry), and albumin checked by BCG method. 
3 Data Analysis  
Data univariate analysis is presented descriptively, displaying average data and standard deviations. 
Test normality of data using Shapiro wilk test. Bivariate analysis uses T-independent test if data is 
distributed normally. If data is not distributed normally used Mann-whitney test. Spearman 
correlation if data is not distributed normall. Difference in means used test Krusla wallis Analysis 
using computer programs SPSS 23 (Statistical Product and for Social Sciences) and confidence 
intervals of 95%, where p< 0.05. 
4 Results 
In table 1, there were 67 NAFLD patients with an average age of 42.1± 11.9  years, 






In table 2, comparison of NAFLD risk factors in normoweight, overweight and obesity, showed very 
significant P<0.001 results 
Parameters n=67, mean±SD 
BMI Kg/M2 24.02±3.7 
RBS mg/dL 210.1±83.8 
SGOT µ/l 58.9±26.9 
SGPT   µ/l 40.3±9.1 
Trombosit  103/ µL 220089.5±85777.8 
Albumin mg/dL 3.3±0.5 
Adiponektin μg/mL 7.1±2.3 
Resistin ng/mL 3.1±0.9 
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BMI Kg/M2 20.8±1.1 24.8±2.4 28.5±1.7 0.001 
RBS mg/dL 148.3±59.7 268.2±61.2 265.3±59.5 0.001 
SGOT µ/l 39.5±13.9 62.4±20.0 87.3±20.1 0.001 
SGPT   µ/l 35.8±7.2 41.4±7.6 46.8±9.1 0.001 
Trombosit  103/ µL 289875.0±60748.9 191133.3±27310.0 130150.0±9.1 0.001 
Albumin mg/dL 3.8±0.4 3.1±0.2 2.8±0.2 0.001 
Adiponektin μg/mL 8.2±1.9 7.1±1.7 5.3±2.3 0.001 
Resistin ng/mL 2.7±0.6 2.9±0.8 3.8±0.9 0.001 
 
In table 3, there is a very significant correlation between BMI and all NAFLD risk factors 
Table 3 The Relationship between BMI and NAFLD risk factors 
Parameters r p 
RBS mg/dL 0.669** 0.001 
SGOT µ/l 0.840** 0.001 
SGPT   µ/l 0.662** 0.001 
Trombosit  103/ µL -0.869** 0.001 
Albumin mg/dL -0.871** 0.001 
Adiponektin μg/mL -0.583** 0.001 
Resistin ng/mL 0.457** 0.001 
5 Discussion  
The earliest events initiating NAFLD reside in an absolute or relative calorie excess, as confirmed by 
the link between NAFLD and obesity. Limited physical activity, sedentary behaviors, and screen 
watching are complementary aspects of calorie imbalance irrespective of BMI. [10] Increased 
substrate flux will overload adipose tissue compartments, leading to dysfunctional adipose tissue, a 
spillover of free fatty acids into non-adipose tissues, de novo lipogenesis, and accumulation of lipids 
in the liver. This process  has been described by Unger as "lipotoxicity". [11] Progression of liver 
disease is extremely variable; pure fatty liver (NAFL) does not reduce life expectancy, whereas 
patients with NASH have increased all-cause and liver-related mortality.  [12] Liver biopsy remains 
the sole method for correct disease classification, but guidelines suggest limiting its use to very 
specific settings. The NAFLD activity score, calculated as the sum of steatosis (0-3), lobular 
inflammation (0-3), and hepatocellular ballooning (0-2), is largely used, but the European SAF 
(Steatosis, Activity, Fibrosis) score more precisely identifies the components of disease progression.  
[13]  Fibrosis is the most ominous predicting factor; it increases on average by one stage over 14.3 
years in patients with NAFL and 7.1 years in patients with NASH. [14] The whole cardiovascular 
system is often involved, driven by the atherogenic profile and features of metabolic syndrome. [15] 
Cardiovascular disease remains the most common cause of death [16]; diffuse atherogenic lesions, 
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such as coronary artery disease and increased carotid intima-media thickness, [17] are more common 
in NAFLD, independent of traditional risk factors. Left ventricular failure and altered cardiac energy 
metabolism have also been described. [18] NAFLD doubled the risk of incident type 2 diabetes in a 
meta-analysis incorporating data from 20 observational studies (nearly 117000 people without 
diabetes), over a median five-year follow-up.  [19] The risk is diminished by resolution of NAFLD, 
[20] pointing to the accumulation of liver fat as a cofactor in the pathogenesis of type 2 diabetes. [21]    
Obese individuals have a 3.5-fold increased risk of developing NAFLD, and there is an obvious dose-
dependent relationship between BMI and NAFLD risk.[22] Individuals with fatty liver, even if they 
were not overweight, are probably complicated by the risk of metabolic syndrome, that is, a fatty liver 
per se also has clinical significance. However, since these pathological findings were also dependent 
on BMI. [23]. In this study there was a difference between the risk factor of NAFLD at each level of 
BMI, and BMI correlated significantly with the risk factor NAFLD. 
6 Conclusion:  
There are very significant correlates between BMI and all inflamatori factors of NFLD. 
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